Chongqing Zhifei Bio Products (SHE:300122) — Market Cap & Net Worth
Market Cap & Net Worth: Chongqing Zhifei Bio Products (300122)
Chongqing Zhifei Bio Products (SHE:300122) has a market capitalization of $5.31 Billion (CN¥36.27 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #3448 globally and #522 in its home market, demonstrating a -0.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chongqing Zhifei Bio Products's stock price CN¥15.15 by its total outstanding shares 2393789747 (2.39 Billion). Analyse Chongqing Zhifei Bio Products (300122) cash conversion ratio to see how efficiently the company converts income to cash.
Chongqing Zhifei Bio Products Market Cap History: 2015 to 2026
Chongqing Zhifei Bio Products's market capitalization history from 2015 to 2026. Data shows growth from $3.85 Billion to $5.31 Billion (5.49% CAGR).
Index Memberships
Chongqing Zhifei Bio Products is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$1.31 Trillion | 0.40% | #53 of 100 |
Weight: Chongqing Zhifei Bio Products's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Chongqing Zhifei Bio Products Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chongqing Zhifei Bio Products's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.35x
Chongqing Zhifei Bio Products's market cap is 0.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.56x
Chongqing Zhifei Bio Products's market cap is 4.56 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.85 Billion | $712.74 Million | $197.40 Million | 5.40x | 19.51x |
| 2016 | $3.50 Billion | $445.95 Million | $32.52 Million | 7.85x | 107.63x |
| 2017 | $5.97 Billion | $1.34 Billion | $432.28 Million | 4.45x | 13.81x |
| 2018 | $8.26 Billion | $5.23 Billion | $1.45 Billion | 1.58x | 5.69x |
| 2019 | $10.72 Billion | $10.59 Billion | $2.37 Billion | 1.01x | 4.53x |
| 2020 | $32.02 Billion | $15.19 Billion | $3.30 Billion | 2.11x | 9.70x |
| 2021 | $27.05 Billion | $30.65 Billion | $10.21 Billion | 0.88x | 2.65x |
| 2022 | $19.17 Billion | $38.26 Billion | $7.54 Billion | 0.50x | 2.54x |
| 2023 | $20.77 Billion | $52.92 Billion | $8.07 Billion | 0.39x | 2.57x |
| 2024 | $9.21 Billion | $26.07 Billion | $2.02 Billion | 0.35x | 4.56x |
Competitor Companies of 300122 by Market Capitalization
Companies near Chongqing Zhifei Bio Products in the global market cap rankings as of May 2, 2026.
Key companies related to Chongqing Zhifei Bio Products by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Chongqing Zhifei Bio Products Historical Marketcap From 2015 to 2026
Between 2015 and today, Chongqing Zhifei Bio Products's market cap moved from $3.85 Billion to $ 5.31 Billion, with a yearly change of 5.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.31 Billion | -19.71% |
| 2025 | CN¥6.61 Billion | -28.25% |
| 2024 | CN¥9.21 Billion | -55.66% |
| 2023 | CN¥20.77 Billion | +8.37% |
| 2022 | CN¥19.17 Billion | -29.12% |
| 2021 | CN¥27.05 Billion | -15.52% |
| 2020 | CN¥32.02 Billion | +198.79% |
| 2019 | CN¥10.72 Billion | +29.67% |
| 2018 | CN¥8.26 Billion | +38.46% |
| 2017 | CN¥5.97 Billion | +70.51% |
| 2016 | CN¥3.50 Billion | -9.12% |
| 2015 | CN¥3.85 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Chongqing Zhifei Bio Products was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.31 Billion USD |
| MoneyControl | $5.31 Billion USD |
| MarketWatch | $5.31 Billion USD |
| marketcap.company | $5.31 Billion USD |
| Reuters | $5.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal P… Read more